Search Results - "Vonk, A.M"

Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids by Zomer-van Ommen, D.D, Vijftigschild, L.A.W, Kruisselbrink, E, Vonk, A.M, Dekkers, J.F, Janssens, H.M, de Winter-de Groot, K.M, van der Ent, C.K, Beekman, J.M

“…Abstract Premature termination codon read-through drugs offer opportunities for treatment of multiple rare genetic diseases including cystic fibrosis. We here…”
Get full text

A bioassay using intestinal organoids to measure CFTR modulators in human plasma by Dekkers, R, Vijftigschild, L.A.W, Vonk, A.M, Kruisselbrink, E, de Winter-de Groot, K.M, Janssens, H.M, van der Ent, C.K, Beekman, J.M

“…Abstract Treatment efficacies of drugs depend on patient-specific pharmacokinetic and pharmacodynamic properties. Here, we developed an assay to measure…”
Get full text

WS18.2 The rainbow project: personalised medicine for CF-patients with rare mutations by van Mourik, P, Berkers, G, Vonk, A.M, de Poel, E, Hagemeijer, M.C, Majoor, C.J, Heijerman, H.G.M, Koppelman, G.H, Roukema, J, Bannier, M.A.G.E, Janssens, H.M, Beekman, J.M, van der Ent, C.K

Get full text

29 Validating the organoid model across European laboratories by van Mourik, P, Berkers, G, Vonk, A.M, Ramalho, A.S, Awatade, N.T, van der Ent, C.K, de Boeck, K, Amaral, M.D, Beekman, J.M

Get full text

WS18.2 Prospective selection of potential CFTR-modifying treatments using intestinal organoids by Berkers, G, Dekkers, J.F, Kruisselbrink, E, Vonk, A.M, Heida-Michel, S, Geerdink, M, de Winter-de Groot, K.M, Arets, H.G.M, Bronsveld, I, van de Graaf, E.A, Majoor, C.J, Koppelman, G.H, Roukema, J, Janssens, H.M, Heijerman, H.G.M, Vries, R.G.J, Clevers, J.C, Jonge, H. de, Beekman, J.M, van der Ent, C.K

Get full text

S11.4 Relationship between organoid swelling and improvement of CFTR function in patients with cystic fibrosis homozygous for the F508del mutation receiving lumacaftor-ivacaftor by Graeber, S.Y., van Mourik, P., Vonk, A.M., Hirtz, S., Mall, M.A., Beekman, J.

Get full text

WS09.1 First results of the HIT-CF ex vivo organoid study show rescue of CFTR with ultra-rare mutations by a novel triple combination of CFTR modulators by Silva, I.A.L., Ramalho, A.S., Vonk, A.M., Bierlaagh, M., Suen, S.W.F., Pott, J., Amaral, M.D., Vermeulen, F., De Boeck, C., Beekman, J.M., van der Ent, K.

Get full text

FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes by de Poel, E., Spelier, S., Hagemeijer, M.C., van Mourik, P., Suen, S.W.F., Vonk, A.M., Brunsveld, J.E., Ithakisiou, G.N., Kruisselbrink, E., Oppelaar, H., Berkers, G., de Winter de Groot, K.M., Heida-Michel, S., Jans, S.R., van Panhuis, H., Bakker, M., van der Meer, R., Roukema, J., Dompeling, E., Weersink, E.J.M., Koppelman, G.H., Blaazer, A.R., Muijlwijk-Koezen, J.E., van der Ent, C.K., Beekman, J.M.

“…•We implemented a high-throughput 384-wells version of the functional FIS assay to screen a large number of PDIOs for compounds that enhance CFTR function.•We…”
Get full text

ePS1.05 High reproducibility of Forskolin-induced swelling of intestinal organoids across three academic laboratories by van Mourik, P., Vonk, A.M., Santo Ramalho, A., Silva, I.A.L., Botelho, H.M., Bor, R., Aguilera, B., Mullenders, J., Boj, S., Vries, R., de Boeck, C., Amaral, M.D., van der Ent, C.K., Beekman, J.M.

Get full text

ePS1.04 In vivo effect of three potentiator treatments found effective in rectal organoids by Berkers, G., van Mourik, P., Vonk, A.M., Kruisselbrink, E., Dekkers, J.F., de Winter - de Groot, K.M., Arets, H.G.M., Heijerman, H., Majoor, C.J., Koppelman, G.H., Roukema, J., Janssens, H.M., van der Meer, R., Vries, R.G.J., de Jonge, H.R., Beekman, J.M., van der Ent, C.K.

Get full text